(24/7 MARKET NEWS) – Talaris Therapeutics, Inc. (Nasdaq: TALS) announced, this morning, that it completed its business and program prospects review and decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was mostly due to the pace of enrollment and the associated timeline to critical milestones. Talaris will continue to enroll its FREEDOM-3 Phase 2 clinical trial evaluating FCR001’s ability to induce tolerance in scleroderma. Talaris also initiated a comprehensive review of strategic alternatives focused on maximizing shareholder value, including possible business combinations and/or a divestiture of the Company’s cell therapy CMC capabilities.
Talaris is at $$1.74, up $0.16 (10.12%), on trading volume of 20 thousand premarket shares.
Its 52-week trading range is $0.89 to $10.56. If it can break through the $1.95 resistance level, on strong volume, its setup is favorable for a potential run to the mid to upper twos.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
